China Blocks Pharma’s Herbal Injection After Three Deaths
This article was originally published in PharmAsia News
Chinese authorities moved to block an herbal injection made by a pharmaceutical firm after three patients died of strong adverse reactions to the Siberian ginseng treatment made by Wandashan Pharmaceuticals. The State FDA ordered use and distribution of the injection suspended after the adverse reactions reported in a single province of the nation. The herbal injections are used to treat thrombosis resulting from weak livers or kidneys, and for curing heart problems. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.